Po Yee Yip

992 total citations
24 papers, 746 citations indexed

About

Po Yee Yip is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Po Yee Yip has authored 24 papers receiving a total of 746 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Po Yee Yip's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Research Studies (5 papers). Po Yee Yip is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Research Studies (5 papers). Po Yee Yip collaborates with scholars based in Australia, United States and United Kingdom. Po Yee Yip's co-authors include Lisa G. Horvath, Maija R.J. Kohonen‐Corish, Wendy A. Cooper, Michael Boyer, Christina Selinger, Brian C. McCaughan, Bing Yu, Sandra A. O’Toole, Trần Nam Thắng and Steven Kao and has published in prestigious journals such as Journal of Clinical Oncology, FEBS Letters and Annals of Oncology.

In The Last Decade

Po Yee Yip

22 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Po Yee Yip Australia 12 460 441 224 179 65 24 746
Shinsuke Hashida Japan 12 345 0.8× 332 0.8× 382 1.7× 225 1.3× 32 0.5× 30 719
Muhammad Alamgeer Australia 13 184 0.4× 346 0.8× 294 1.3× 176 1.0× 36 0.6× 25 615
Ruixuan Geng China 12 196 0.4× 254 0.6× 234 1.0× 148 0.8× 66 1.0× 29 556
Huili Chu China 12 187 0.4× 276 0.6× 442 2.0× 244 1.4× 65 1.0× 15 710
Xianping Yi China 4 342 0.7× 476 1.1× 195 0.9× 160 0.9× 143 2.2× 9 680
Kuan‐Li Wu Taiwan 12 216 0.5× 204 0.5× 302 1.3× 247 1.4× 67 1.0× 36 603
Takumi Yamaura Japan 13 215 0.5× 329 0.7× 200 0.9× 172 1.0× 156 2.4× 38 603
Inés López Spain 10 198 0.4× 280 0.6× 396 1.8× 258 1.4× 44 0.7× 18 664
Zaoke He China 7 199 0.4× 299 0.7× 197 0.9× 202 1.1× 150 2.3× 8 545
Liam F. Spurr United States 11 161 0.3× 286 0.6× 238 1.1× 158 0.9× 60 0.9× 28 515

Countries citing papers authored by Po Yee Yip

Since Specialization
Citations

This map shows the geographic impact of Po Yee Yip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po Yee Yip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po Yee Yip more than expected).

Fields of papers citing papers by Po Yee Yip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po Yee Yip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po Yee Yip. The network helps show where Po Yee Yip may publish in the future.

Co-authorship network of co-authors of Po Yee Yip

This figure shows the co-authorship network connecting the top 25 collaborators of Po Yee Yip. A scholar is included among the top collaborators of Po Yee Yip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po Yee Yip. Po Yee Yip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bray, Victoria, Po Yee Yip, Anthony Linton, et al.. (2024). Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer. Journal of Geriatric Oncology. 15(2). 101705–101705. 7 indexed citations
2.
Subramaniam, Shalini, Diana Adams, Annette Tognela, et al.. (2024). Patients' perception of the benefits of palliative systemic therapy for advanced cancer. Internal Medicine Journal. 54(5). 735–741.
3.
Pal, Abhijit, Adnan Nagrial, Jenny Lee, et al.. (2023). Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. 20(1). 16–24. 4 indexed citations
4.
Yip, Po Yee, et al.. (2023). A comparison of the outcomes of pulmonary versus extrapulmonary extensive‐stage small cell carcinoma. Internal Medicine Journal. 54(3). 414–420.
5.
Pal, Abhijit, Victoria Bray, Po Yee Yip, et al.. (2023). Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer. Internal Medicine Journal. 54(4). 596–601. 3 indexed citations
6.
7.
Itchins, Malinda, Hannah C. Ainsworth, Marliese Alexander, et al.. (2022). A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. Clinical Lung Cancer. 23(8). 702–708. 3 indexed citations
8.
9.
Itchins, Malinda, Shuang Liang, T. Barnes, et al.. (2021). P24.03 Dynamic Circulating Tumor DNA Interim Results From The ALKternate Clinical Trial. Journal of Thoracic Oncology. 16(10). S1030–S1032. 2 indexed citations
10.
Roberts, Tara L., Wei Chua, Therese M. Becker, et al.. (2017). Clinical outcomes in patients with advanced epidermal growth factor receptor‐mutated non‐small‐cell lung cancer in South Western Sydney Local Health District. Internal Medicine Journal. 47(12). 1405–1411. 14 indexed citations
11.
12.
Cooper, Wendy A., Trần Nam Thắng, Ricardo E. Vilain, et al.. (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 89(2). 181–188. 236 indexed citations
13.
14.
Tognela, Annette, Kevin J. Spring, Therese M. Becker, et al.. (2014). Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician's perspective. Critical Reviews in Oncology/Hematology. 93(2). 90–102. 31 indexed citations
15.
Yip, Po Yee, Bing Yu, Wendy A. Cooper, et al.. (2013). Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology. 8(4). 408–414. 36 indexed citations
16.
Cooper, Wendy A., Bing Yu, Po Yee Yip, et al.. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology. 66(9). 744–748. 20 indexed citations
17.
Selinger, Christina, Prudence A. Russell, Sandra O’Toole, et al.. (2013). Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology. 26(12). 1545–1553. 125 indexed citations
18.
Yip, Po Yee, Wendy A. Cooper, Maija R.J. Kohonen‐Corish, et al.. (2013). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology. 67(4). 333–340. 12 indexed citations
19.
Yip, Po Yee, James G. Kench, Krishan Rasiah, et al.. (2011). Low AZGP1 expression predicts for recurrence in margin‐positive, localized prostate cancer. The Prostate. 71(15). 1638–1645. 34 indexed citations
20.
Major, Louise L., et al.. (2002). Tandem termination signals: myth or reality?. FEBS Letters. 514(1). 84–89. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinsuke Hashida Breakdown of academic impact, for papers by Muhammad Alamgeer Breakdown of academic impact, for papers by Ruixuan Geng Breakdown of academic impact, for papers by Huili Chu Breakdown of academic impact, for papers by Xianping Yi Breakdown of academic impact, for papers by Kuan‐Li Wu Breakdown of academic impact, for papers by Takumi Yamaura Breakdown of academic impact, for papers by Inés López Breakdown of academic impact, for papers by Zaoke He Breakdown of academic impact, for papers by Liam F. Spurr
Rankless by CCL
2026